Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

108.97 -2.51 (-2.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
64 65 Next >
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
From Pfizer Inc.
Via Business Wire
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
Moderna, BioNTech Jump After CDC Green-Lights Updated Covid Boosters
These new shots target the BA.4 and BA.5 subvariants of omicron. 
Via Investor's Business Daily
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Europe Backs Approval Of Omicron-Adapted COVID-19 Vaccines
Health Canada has approved Moderna Inc's (NASDAQ: 
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
From Pfizer Inc.
Via Business Wire
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
Wall Street Journal 
Via Benzinga
Why Novavax Shares Are Getting Hammered After Moderna, Pfizer And BioNTech News
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 6.76% to $32.84 Wednesday afternoon in possible reaction to competitor Moderna Inc (NASDAQ: MRNA) receiving FDA authorization for emergency use... 
Via Benzinga
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
From Pfizer Inc.
Via Business Wire
Pfizer, Moderna Nab FDA Authorization For Updated Covid Boosters
Boosters are recommended two months out from the last shot. 
Via Investor's Business Daily
Benzinga Before The Bell: Tesla Sues Louisiana Automobile Dealers Association, Will iPhone 14 Feature Satellite Connectivity?, Netflix Denies $7 To $9 Ad-Supported Plan And Other Top Financial Stories Tuesday, August 30
Reuters Taiwan’s China Airlines Orders 16 Boeing 787s 
Via Benzinga
US Stock Futures Higher Ahead Of Economic Data, Fed Speakers
Pre-open movers U.S. stock futures traded higher in early pre-market trade as investors digested comments from Federal Reserve Chairman Jerome Powell. Markets closed lower again on Monday, with the... 
Via Benzinga
Pfizer-BioNTech, Moderna Set To Get FDA Nod For Omicron Booster Shots As Early As Wednesday: Report
Booster shots for Omicron variants of the novel coronavirus could officially be made available in the U.S. just after Labor Day, Politico reported on Monday. 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Pfizer/BioNTech Complete European Submission For Omicron Subvariant Adapted Vaccine
Via Benzinga
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
From Pfizer Inc.
Via Business Wire
Moderna Claims Pfizer, BioNTech Stole Its Patented Tech In Covid Shot
The lawsuit alleges Comirnaty violates Moderna's patents from 2010-16. 
Via Investor's Business Daily
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has  
Via Benzinga
Pfizer And Moderna Are In A Race With Omicron; Will The Vaccine Stocks Be Too Late?
The companies hope to launch updated boosters this fall. This is what experts think of their prospects. 
Via Investor's Business Daily
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
In a Reuters report, AstraZeneca Plc's (NASDAQ: 
Via Benzinga
Moderna Asks FDA To Sign Off On Its Updated Covid Booster Shot
Moderna put the finishing touches on its FDA filing Tuesday, trailing its rivals by a day. 
Via Investor's Business Daily
Pfizer/BioNTech's COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have  
Via Benzinga
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here's Who May Be Rolling Them Out
Via Benzinga
Face Of US COVID-19 Response, Dr Anthony Fauci To Retire In December
  
Via Benzinga
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Benzinga Before The Bell: Apple Employees Resist Calls For Return-To-Office, Tesla About To Hike FSD Prices Again, MGM China Injects $594M Into Macau Unit And Other Top Financial Stories Monday, August 22
Reuters Vodafone To Sell Hungarian Business For $1.8B: Report 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
64 65 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.